发明授权
EP1001945B1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
失效
喹啉和血小板源性系数和/或P56 LCK酪氨酸激酶抑制喹喔啉的DEN
- 专利标题： QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
- 专利标题（中）： 喹啉和血小板源性系数和/或P56 LCK酪氨酸激酶抑制喹喔啉的DEN
-
申请号： EP98925041.0申请日： 1998-05-28
-
公开(公告)号： EP1001945B1公开(公告)日： 2011-03-02
- 发明人: MYERS, Michael, R. , HE, Wei , SPADA, Alfred, P. , MAGUIRE, Martin, P.
- 申请人： Aventis Pharmaceuticals Inc.
- 申请人地址： 55 Corporate Drive Bridgewater, NJ 08807 US
- 专利权人： Aventis Pharmaceuticals Inc.
- 当前专利权人： Aventis Pharmaceuticals Inc.
- 当前专利权人地址： 55 Corporate Drive Bridgewater, NJ 08807 US
- 代理机构： Adamson Jones
- 优先权： US864455 19970528; US972614 19971118
- 国际公布： WO1998054158 19981203
- 主分类号： C07D241/52
- IPC分类号： C07D241/52 ; C07D401/04 ; C07D405/04
摘要：
This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
公开/授权文献
信息查询
